Last Updated: 17/12/2024
The Haiti Malaria Elimination Consortium (HaMEC)
Objectives
HaMEC will develop, adopt, and implement an evidence-based strategy and operational plan for achieving malaria elimination; secure the additional financial resources needed to achieve elimination; improve and refine malaria surveillance systems to support decision-making and action; and reduce malaria transmission through implementation of effective community-based interventions that are tailored to the level of malaria risk in high-prevalence areas, ultimately leading to elimination by 2020.
Specific objectives include to:
- Assess the performance of the targeted malaria elimination (TME) strategy as measured against set targets so that the TME strategy can be improved and adapted to address any operational issues that are identified;
- Document where indigenous malaria transmission has been successfully interrupted, as well as where it has not, in an effort to focus TME strategies accordingly;
- Identify program and external factors that lead to the success and failure of achieving malaria elimination; and
- Track the overall progress towards malaria elimination in Haiti as a precursor to elimination certification.
Centers for Disease Control and Prevention (CDC), United States
Clinton Health Access Initiative (CHAI), United States
Ministry of Public Health and Population Haiti
Dominican Republic Ministry of Public Health
Pan American Health Organization (PAHO), United States
The Carter Center, United States
Tulane University, United States
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
In regards to the specific objective 1, Sulfadoxine-Pyrimethamine + Primaquine (single low dose) will be administered as 1 yearly round DOT during a house-to-house campaign.
Type: Interventional
Allocation: Non-randomized
Intervention model: Single group
Masking: None (open label)
Primary purpose: To assess effectiveness, feasibility, acceptability, and safety of the package of interventions
Druetz T. (2021) - PMID: 33993294Druetz T. (2020) - PMID: 32571323Rogier E. (2020) - PMID: 32310062
Combination of Interventions
Drug Resistance
Drug-based Strategies
Financing & Economics
Health Systems
Impact of Interventions
Leadership & Governance
Surveillance
Jan 2014 — Mar 2021
$30.87M
